• Sharp Therapeutics held its annual meeting of shareholders on July 21, 2026.
• Shareholders set the board size at six directors.
• Shareholders reappointed MNP LLP as auditor, authorizing the board to set the auditor’s remuneration.
• Shareholders reapproved the company’s rolling 10% stock option plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sharp Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607211700NEWSFILECNPR____20260721_305977_1) on July 21, 2026, and is solely responsible for the information contained therein.